Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
Home Print this page Email this page Small font size Default font size Increase font size Users Online: 1037
Year : 2018  |  Volume : 19  |  Issue : 2  |  Page : 120-123

Therapy for involuting infantile hemangioma: Propranolol effectiveness

1 Department of Dermatology, National Institute of Pediatrics, City, Mexico
2 Department of Cardiology, National Institute of Pediatrics, City, Mexico

Correspondence Address:
Luz Orozco-Covarrubias
Department of Dermatology, National Institute of Pediatrics, Insurgentes Sur 3700-C, Col. Insurgentes-Cuicuilco, 04530 Mexico, D.F
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/ijpd.IJPD_40_17

Rights and Permissions

Background/Objectives: The efficacy of propranolol as a treatment for infantile hemangiomas (IHs) has been documented. Until now, little has been written about the role of propranolol beyond the proliferation phase of IH. Our aim was to document propranolol efficacy and safety in the treatment of involutive IH. Patients and Methods: Two evaluations were conducted. Investigators evaluated the final clinical results by comparing clinical data at baseline and at the end of the study. Evaluators scored each panel of photographs and were blinded from any clinical information. Both groups used the same scoring system. Patients treated with propranolol in our department between 2009 and 2014 were reviewed. Results: A total of 15 patients with involuting IH treated with propranolol were eligible. Eleven (73%) were females, ranging in age between 16 and 110 months (median 41 months). The types of IH were mixed (n = 13) and superficial (n = 2). The median duration of the propranolol treatment was 20 months (range 6–33 months). The mean size reduction was from 6 cm ± 4.33 before the treatment to 3.98 ± 1.25 at the end of the treatment. The general mean involution according to the investigators' evaluation was 4.1 ± 2.7. The general mean involution according to the evaluators' evaluation was 4.9 ± 1.5. Telangiectasias showed no response. Recurrence was observed in one patient. Transient nightmares were documented in one patient, and nighttime awakenings were documented in another. The therapy was discontinued in neither of these patients. Conclusions: In our experience, propranolol was well tolerated and associated with limited adverse reactions. The use of oral propranolol was effective in the treatment of IH beyond the proliferative phase.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded252    
    Comments [Add]    

Recommend this journal